Tang et al., 2013 - Google Patents
Protein isoform-specific validation defines multiple chloride intracellular channel and tropomyosin isoforms as serological biomarkers of ovarian cancerTang et al., 2013
View PDF- Document ID
- 6514882728877811576
- Author
- Tang H
- Beer L
- Tanyi J
- Zhang R
- Liu Q
- Speicher D
- Publication year
- Publication venue
- Journal of proteomics
External Links
Snippet
New serological biomarkers for early detection and clinical management of ovarian cancer are urgently needed, and many candidates have been reported. A major challenge frequently encountered when validating candidates in patients is establishing quantitative …
- 102000004169 proteins and genes 0 title abstract description 110
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
- G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electro-chemical, or magnetic means
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tang et al. | Protein isoform-specific validation defines multiple chloride intracellular channel and tropomyosin isoforms as serological biomarkers of ovarian cancer | |
| Li et al. | Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry | |
| Washam et al. | Identification of PTHrP (12-48) as a plasma biomarker associated with breast cancer bone metastasis | |
| US10338076B2 (en) | Methods and compositions for the diagnosis of ovarian cancer | |
| Sandow et al. | Discovery and validation of novel protein biomarkers in ovarian cancer patient urine | |
| EP2130048B1 (en) | Apex as a marker for lung cancer | |
| US20140274794A1 (en) | Methods and Compositions for Diagnosis of Ovarian Cancer | |
| CN110799841B (en) | Biomarker for detecting colorectal cancer | |
| CA2453580A1 (en) | Detection of ovarian cancer based upon alpha-haptoglobin levels | |
| Navarro-Muñoz et al. | Uromodulin and α1-antitrypsin urinary peptide analysis to differentiate glomerular kidney diseases | |
| CA2700125A1 (en) | Detection of saliva proteins modulated secondary to ductal carcinoma in situ of the breast | |
| JP2013515272A (en) | Epidermal growth factor receptor (EGFREGFR) protein SRM / MRM assay | |
| Yang et al. | Identification of novel serum peptides biomarkers for female breast cancer patients in Western China | |
| US20120040376A1 (en) | Lung cancer diagnostic polypeptide, method for detecting lung cancer, and method for evaluating therapeutic effect | |
| Wang et al. | Identification of urine biomarkers associated with lung adenocarcinoma | |
| Zhang et al. | A prognostic biomarker for gastric cancer with lymph node metastases | |
| CA3064702A1 (en) | Novel stool-based protein biomarkers for colorectal cancer screening | |
| Araumi et al. | Urinary and plasma proteomics to discover biomarkers for diagnosing between diabetic nephropathy and minimal change nephrotic syndrome or membranous nephropathy | |
| Yang et al. | Identification of novel low molecular weight serum peptidome biomarkers for non‐small cell lung cancer (NSCLC) | |
| CA2746128C (en) | Biomarker for diagnosis, prediction and/or prognosis of acute heart failure and uses thereof | |
| Pinet et al. | Predicting left ventricular remodeling after a first myocardial infarction by plasma proteome analysis | |
| WO2012122094A2 (en) | Biomarkers of cardiac ischemia | |
| Chen et al. | SELDI protein chip technology for the detection of serum biomarkers for liver disease | |
| Petri et al. | Comparison of proteomic biomarker panels in urine and serum for ovarian cancer diagnosis | |
| Li et al. | Analysis of the raw serum peptidomic pattern in glioma patients |